Advertisement
Advertisement
GMAB
Genmab A/S ADS
34.36
USDSponsored
+1.34
+4.06%
Aug 25, 15:59 UTC -4
Closed
Pre-Market
34.14
-0.22
-0.64%
GMAB Earnings Reports
Positive Surprise Ratio
GMAB beat 27 of 42 last estimates.
64%
Next Report
Date of Next Report
Nov 05, 2026
Estimate for Q3 26 (Revenue/ EPS)
$1.23B
/$4.00
Implied change from Q2 26 (Revenue/ EPS)
+6.92%
/-18.53%
Implied change from Q3 25 (Revenue/ EPS)
+20.83%
/-38.08%
Genmab A/S ADS earnings per share and revenue
On Aug 06, 2026, GMAB reported earnings of 4.91 USD per share (EPS) for Q2 26, beating the estimate of 3.59 USD, resulting in a 36.61% surprise. Revenue reached 1.16 billion, compared to an expected 1.13 billion, with a 1.98% difference. The market reacted with a +1.95% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 6 analysts forecast an EPS of 4.00 USD, with revenue projected to reach 1.23 billion USD, implying an decrease of -18.53% EPS, and increase of 6.92% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Alvotech Ordinary Shares
Report Date
Aug 19, 2026 For Q2 26
Estimate
-$0.02
Actual
-$0.11
Surprise
-300.00%
Cabaletta Bio, Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.34
Surprise
+10.69%
Abeona Therapeutics Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.23
Actual
-$0.35
Surprise
-49.19%
Prenetics Global Limited Class A Ordinary Share
Report Date
Aug 18, 2026 For Q2 26
Estimate
-$0.71
Actual
-$0.53
Surprise
+26.30%
Fate Therapeutics, Inc.
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.27
Actual
-$0.25
Surprise
+8.49%
ProMIS Neurosciences Inc. Common Shares (ON)
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$1.39
Actual
-$1.28
Surprise
+8.07%
TuHURA Biosciences, Inc. Common Stock
Report Date
Aug 14, 2026 For Q2 26
Estimate
-$0.14
Actual
-$0.14
Surprise
+5.34%
Outlook Therapeutics, Inc. Common Stock
Report Date
Aug 14, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.09
Surprise
+5.46%
Elutia Inc. Class A Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.15
Actual
-$0.17
Surprise
-11.11%
Lantern Pharma Inc. Common Stock
Report Date
Aug 14, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.28
Surprise
+27.76%
FAQ
What were Genmab A/S ADS's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Genmab A/S ADS reported EPS of $4.91, beating estimates by 36.61%, and revenue of $1.16B, 1.98% above expectations.
How did the market react to Genmab A/S ADS's Q2 2026 earnings?
The stock price moved up 1.95%, changed from $29.26 before the earnings release to $29.83 the day after.
When is Genmab A/S ADS expected to report next?
The next earning report is scheduled for Nov 05, 2026.
What are the forecasts for Genmab A/S ADS's next earnings report?
Based on 6
analysts, Genmab A/S ADS is expected to report EPS of $4.00 and revenue of $1.23B for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement